Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Petroleum D4
Incorrect expiry date labelling was found: the packaging shows 02.2022, while the correct date is 09.2022. Potential effects: possible premature disposal of the medicine or doubts about its validity.
Lignocain 2%
A foreign body was identified in an individual immediate container, i.e. in a 20 ml vial of the Lignocain 2% solution for injection. Potential effects: infection, inflammatory reactions, local and systemic complications, including life-threatening conditions.
Febrisan
A quality defect was found consisting of micro-damages in the structure of the primary packaging foil, which may lead to loss of tightness and deterioration of the medicine’s quality. Potencjalne skutki: reduced treatment efficacy or adverse reactions.
Silimax
Irregularities in batch number labelling were found: containers with batch number 05022020 were packed into cartons incorrectly marked as 02022020, preventing unambiguous identification of the product batch. Potential effects: risk of mix-ups and hindered recall in case of safety issues.
Formoterol Easyhaler
A quality defect of the Easyhaler inhaler was found in the reservoir chamber containing the inhalation powder; the impact of this defect on the quality and correct dosing of the medicinal products cannot be excluded, creating a potential risk to patients’ health or life. Potential effects: lack of efficacy, disease exacerbation, respiratory complications.
Bufomix Easyhaler
A quality defect was identified in the Easyhaler inhaler, in the reservoir chamber containing the inhalation powder; as a defect of the immediate packaging it may affect the medicinal product quality and dose delivery. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.
Nitroxolin forte
An impurity 5,7-Dinitro-8-quinolinol (DNC) was identified in the active substance and classified as a mutagenic impurity, whose content should be lower than currently approved limits. Potential effects: increased risk of DNA damage, cancer and other complications.
Hemkortin-HC
Incorrect strength of the medicinal product was found on the immediate (tube) packaging, which may mislead patients or medical staff about the dose being used. Potential effects: improper dosing, lack of therapeutic efficacy or increased adverse reactions.
Biodacyna
A quality defect was found: an out‑of‑specification result for the colour parameter in a parenterally administered medicinal product, which entails a potential risk to patients’ health or life. Potential effects: complications after intravenous or intramuscular administration, lack of treatment safety.
Tlen medyczny Air Products
An unusual odour was detected in one of the cylinders from the batch of the medicinal product Medical oxygen Air Products, indicating a quality defect of the medical gas and a potential health risk to patients when used. Potential effects: irritation of the respiratory tract, unspecified adverse reactions, lack of safety of oxygen therapy.
Zerbaxa
Microbiological contamination was detected in batches of Zerbaxa, indicating a quality defect that may pose a real risk to patients’ health or life. Potential effects: infection, sepsis, treatment complications, lack of therapeutic efficacy.
Tramal
A quality defect was found consisting of unglued outer packaging of the product, which may affect the safety and correct use of the medicine. Potential effects: possible compromise of packaging integrity, risk of improper use or dosing errors.
Triderm
The occurrence of incorrect information on the outer packaging regarding the repackaging site and the name of the parallel importer was classified as a quality defect of the medicinal product. Potential effects: incorrect use of the drug, inability to identify the responsible entity, possible therapy complications.
Lisinoratio 5
Suspected contamination of the batch of Lisinoratio 5, 5 mg, tablets with ibuprofen as an undesired substance, which is a potential quality defect that may endanger patients’ health. Potential effects: adverse reactions, drug interactions, complications involving kidneys and cardiovascular system.
Oxydolor
Stability studies of the product batches showed an out-of-specification result for active substance content, which may lead to incorrect dosing of the medicine. Potential effects: lack of treatment efficacy or overdose, complications, risk to health.
Krople uspokajające spokojne
the tested sample of the medicinal product Krople uspokajające spokojne did not meet the requirements specified in the product documentation for total aerobic microbial count (TAMC). This quality defect may pose a potential risk to the health or life of patients. Potential effects: infections, complications, health risk.
Gliceryna
It was found that test results for batches of the pharmaceutical raw material GLICERYNA 85% are out of specification for the parameters: aldehydes and sugars, which means failure to meet established quality requirements for a medicinal product. Potential effects: reduced quality of preparations, possible irritation or other adverse reactions.
Allergo-Comod
Irregularities in the assembly of the dispenser pump housing were found, causing incorrect drop size or inability to dispense drops from the bottle. Potential effects: lack of treatment efficacy, worsening of allergy symptoms, possible discomfort or eye irritation.
Timo-COMOD 0,5 %
Irregularities in the assembly of the dispenser pump housing were found, resulting in improper drop size or inability to dispense drops from the dispenser. Potential effects: lack of treatment efficacy, incorrect dosing, possible worsening of the eye condition.
Minirin
In some packs, an incorrect liquid volume and results not complying with the specification for desmopressin and benzalkonium chloride content were found, meaning the dose and safety of the product cannot be assured. Potential effects: lack of treatment efficacy or overdose, adverse reactions, complications.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.